O. Marchetti

Discipline

Sociologie (3) Science politique (2) Psychologie (1) Géographie (1)

Type de document

Articles (35) Recensions (6)

Type de document

Mémoires, Thèses et HDR (1)

Co-auteur

Date

Date

Source

Source

Mot-clé

Treatment (24) Patients (22) Patients (22) Human beings (21) thérapie (20) Therapeutics (20) Infections (13) Infection (12) Candidiasis (12) Candida (12) infection (11) adulte (11) Methods (11) Mycoses (11) Methods (11) adulte (11) temps (durée) (10) Time (10) Blood (10) Older people (10) Use (10) Cases (9) Management (9) Cases (9) hôpital (8) épidémiologie (8) Epidemiology (8) Epidemiology (8) Days (8) Critically ill (8)

Mot-clé

Development (1) Employment (1) Variation (1) Treatment (1) Clinical pharmacology (1) Sports records (1) Signs and symbols (1) Progress (1) Prediction theory (1) Mycoses (1) Miracles (1) Medical microbiology (1) Liquids (1) Licenses (1) International organization (1) Impact (1) High pressure (Technology) (1) High pressure (Science) (1) Evidence (1) Division (1) Communicable diseases (1) Clinics (1) Candida (1) Breast (1) Blood plasma (1) Athletic ability (1) Use studies (1) Use studies (1) Technique (1) Toxicology (1)

Documents écrit par O. Marchetti (35) | parle de O. Marchetti (1)

SARS-CoV-2 neutralizing antibody response in vaccinated and non-vaccinated hospital healthcare workers with or without history of infection.
D. Jacot et al. (2023)
Dosing strategies of imipenem in neonates based on pharmacometric modelling and simulation.
K. Dao et al. (2 févr. 2022)
Increasing morbidity and mortality of candidemia over one decade in a Swiss university hospital.
J. Battistolo et al.
Trends of the Epidemiology of Candidemia in Switzerland: A 15-Year FUNGINOS Survey.
K.M. Adam et al.
The dark side of SARS-CoV-2 rapid antigen testing: screening asymptomatic patients.
G. Caruana et al.
Validation and clinical application of a multiplex high performance liquid chromatography - tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections.
L.A. Decosterd et al. (10 nov. 2020)
Performance of the T2Candida Panel for the Diagnosis of Intra-abdominal Candidiasis.
F. Lamoth et al.
Epidemiology and outcome of fungemia in a cancer Cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031).
O.A. Cornely et al. (2015)
Acquired Multidrug Antifungal Resistance in Candida lusitaniae during Therapy.
S.A. Asner et al. (2015)
Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group.
R. Herbrecht et al. (2015)
European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia.
D. Averbuch et al. (2013)
Voriconazole-induced periostitis.
C. Rossier et al.
β-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3).
F. Lamoth et al. (2012)
Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.
T. Buclin et al. (2012)
Diagnosis of invasive candidiasis in the ICU.
P. Eggimann et al. (2011)
Is (1→3)-β-D-glucan the missing link from bedside assessment to pre-emptive therapy of invasive candidiasis?
P. Eggimann et al. (2011)
Treatment and timing in invasive mould disease.
J. Maertens et al. (2011)
Monitoring procalcitonin in febrile neutropenia: what is its utility for initial diagnosis of infection and reassessment in persistent Fever?
J.O. Robinson et al. (2011)
Caspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients.
L. Senn et al. (2009)
Imipenem underdosing as a cause of persistent neutropenic fever?
F. Lamoth et al. (2009)
An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients.
C. Viscoli et al. (2009)
On track to limit antifungal overuse!
P. Eggimann et al. (2009)
1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia.
L. Senn et al.
Reply to Pasqualotto and Sukiennik
L. Senn et al. (2008)
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
A. Pascual et al. (2008)

next
Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods, [and] Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes
A. Pascual (2010)